John Eng and his colleagues bought Gila monster venom from a supplier and separated it into its chemical parts. One of those parts was a peptide, a chain of 39 amino acids. They named it exendin-4.
Their 1992 paper describes how they worked out its sequence and made a synthetic version. Both the natural and synthetic peptides produced similar responses in an experiment with guinea-pig pancreatic cells. A medicine could be built from the molecule they had identified. Eng et al., Journal of Biological Chemistry, 1992
Thirteen years later, the FDA approved synthetic exendin-4, called exenatide, as Byetta for type 2 diabetes. It became the first approved drug in the GLP-1 receptor agonist class, the family that later included semaglutide.
The lizard supplied a useful chemical design. Human trials had to establish what that design could do for patients. Following those two steps helps explain why drugs that share a receptor can still have different uses and results.
Your gut sends the pancreas an early message
Eating starts a conversation between organs. As nutrients reach the gut, intestinal cells release hormones that help the body handle the incoming food. One is glucagon-like peptide-1, or GLP-1.
GLP-1 helps pancreatic beta cells, the cells that make insulin, release more of it when blood glucose is elevated. Insulin then helps tissues take up glucose. This link between the gut and insulin release is part of the incretin effect.
Researchers had a clue to that connection before they identified the hormone. Glucose taken through the digestive system caused a stronger insulin response than glucose delivered directly into the bloodstream. Something about the route through the gut was adding a signal. NIDDK discovery history
That signal offered a possible treatment for type 2 diabetes, where the body's insulin response cannot keep blood glucose under adequate control. A drug that strengthens the response when glucose rises could help the pancreas meet the demand.
There was a practical obstacle. Natural GLP-1 breaks down within minutes in the bloodstream. A promising action in the body is only part of making a useful medicine. The molecule also has to remain available long enough to work.
Exendin-4 could activate the same receptor and last longer
A receptor is a protein that receives a chemical signal and starts a response in a cell. Exendin-4 could activate the human GLP-1 receptor even though its amino-acid sequence differed from the human hormone.
Its structure also helped it resist breakdown. That gave researchers a candidate with activity lasting much longer than natural GLP-1. The NIDDK's account describes this greater stability as a key step toward a practical diabetes treatment. NIDDK
The original discovery experiment was narrower than the eventual clinical story. Eng's team studied cells from the part of the guinea-pig pancreas involved in digestive secretions. They measured a signal inside those cells. Their paper did not show that a patient with diabetes would improve.
It did give researchers a defined molecule they could reproduce. Exenatide is manufactured synthetically with the same chemical structure as exendin-4. The animal was the source of the discovery; the medicine could then be produced without putting crude venom into a patient.
Conceptual receptor illustration. The peptide shapes are teaching models, not atomic structures. Both can activate the GLP-1 receptor; their duration and clinical use differ.
Byetta's label gives exenatide a mean terminal half-life of 2.4 hours. Half-life describes how quickly the amount in the body falls during that phase of elimination. It does not mean all effects stop at that moment. Byetta prescribing information
A longer-lived molecule had solved an important delivery problem. The next test was whether it improved glucose control over months of use.
The pivotal trials followed 1,446 people
The original approval program included three 30-week randomized trials. Participants had type 2 diabetes that was not adequately controlled by their existing oral medicine. One trial enrolled people taking metformin, another people taking a sulfonylurea, and the third people taking both.
Each group continued its background treatment. Researchers added either exenatide or a placebo injection. This design asked what extra benefit the new medicine provided on top of care the participants already received.
The main measure was HbA1c, often shortened to A1C. Glucose attaches to hemoglobin, the oxygen-carrying protein in red blood cells. Measuring the proportion with glucose attached gives an estimate of average blood glucose over roughly three months. NIDDK, the A1C test
At the higher exenatide dose studied, the FDA's review reports an average A1C reduction of 0.86 percentage points in the metformin trial. The placebo group's average was essentially unchanged. In the other two trials, the treatment difference was close to one percentage point.
Least-squares mean changes in A1C from the FDA's 2005 medical review, Table 1. Higher-dose exenatide groups and their placebo groups continued the named oral medicines. Values are percentage-point changes over the 30-week studies.
Those units matter. An A1C change from 8.2% to 7.3% is a fall of 0.9 percentage points. Reading that as a 0.9% relative change would make the effect look much smaller than it was.
The FDA reviewer judged the improvement clinically meaningful. The results established glucose control in the studied population. The trials were not designed to show whether treatment prevented heart attacks or extended life. Those outcomes require their own studies. FDA medical review, 2005
Weight changed alongside glucose
The same trial program also measured body weight. In the metformin study, the current label reports an adjusted average loss of 2.6 kilograms in the higher-dose exenatide group and 0.2 kilograms in the placebo group. The between-group difference was 2.4 kilograms over 30 weeks.
That finding added another reason to study the treatment. The drug could improve glucose control while weight also fell. But the participants had type 2 diabetes, and the result belongs to this medicine, dose and study. It cannot supply the weight-loss estimate for a different GLP-1 product.
Adjusted mean weight changes from the current Byetta label, Table 8. Exenatide 10-microgram twice-daily group after initial titration versus placebo; 113 participants in each group. Both groups continued metformin. This is a historical trial result, not a dosing recommendation.
Treatment brought costs as well as benefits. Across the original controlled studies, nausea affected 44% of exenatide recipients and 18% of placebo recipients. Seven percent of the exenatide group withdrew because of an adverse event, compared with 3% of the placebo group. The FDA review describes nausea as more frequent early in treatment.
The other medicines a person took also mattered. In the metformin-only trial, low-blood-sugar episodes occurred in about 5% of both groups. The risk rose when exenatide was used with a sulfonylurea, a medicine that stimulates insulin release. The same new drug can create a different treatment problem when the background medication changes. FDA review
Current prescribing information includes warnings about pancreatitis, severe gastrointestinal reactions and kidney injury associated with dehydration. A clinician needs the person's medication list and health history when assessing those risks. Byetta's indication is blood-glucose control in adults with type 2 diabetes, alongside diet and exercise. Current label
Later GLP-1 medicines use different molecular designs
Exenatide helped establish that activating the GLP-1 receptor could become a useful treatment. Later drug development found other ways to keep that signal active.
Semaglutide, for example, is an analogue of human GLP-1. Its design allows it to bind to albumin, a protein in the blood, and resist enzymatic breakdown. The FDA's pharmacology review describes how those properties help prolong its presence in the body. Its molecular starting point differs from exenatide's. FDA semaglutide review
A shared receptor tells you something about how medicines work. To decide what a particular product can achieve, you still need its human studies. The trial population and outcome have to match the question you care about. A diabetes study that measures A1C and an obesity study that measures weight are answering different questions.
Make the treatment goal specific
If you are discussing a GLP-1 medicine with a clinician, write down the exact product and the main result you hope to improve. Bring your current medicines. Ask which measurement will show whether treatment is helping and when it should be checked again.
For glucose control, that discussion can include your A1C and an individual target. For weight treatment, ask for evidence from the relevant product and population. Discuss symptoms that need a call and how side effects will be handled, so the follow-up has a clear purpose.
Which drug discovery should I trace next? Reply with the medicine's name.
For entertainment and education only. Not medical advice. Talk to your doctor before starting anything.